The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics.
The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.
The company said that by the end of June it would have made available more than 500,000 kits, which allow individuals to self-collect nasal samples at home.
The recommendations are intended to improve testing capacity for SARS-CoV-2 by providing ways to combat testing supply shortages and expanding funding, among other steps.
The assays quantitatively measure the activity of galactose-1-phosphate uridylyltransferase and biotinidase enzymes from newborn dried blood spot specimens.
The decline was attributed to SARS-CoV-2's impact on sales of Trinity's infectious disease and diabetes products, as well as its autoimmune testing services.
The bills would award grants to help public health laboratories purchase high-throughput instruments and to help support diagnostic testing outside of the lab setting.
The Dutch firm announced a deal earlier in the month to develop the test with Duke-NUS Medical School and the Diagnostics Development Hub in Singapore.
